HRCT findings of Atypical Adenomatous Hyperplasia.

By Dr Deepu






Focal area of ground glass attenuation on Left Upper Lobe. Rest of the appearances are unremarkable.
 Atypical Adenomatous Hyperplasia (AAH) of the human lung has been recently implicated as a possible precursor lesion of bronchioloalveolar carcinoma (BAC). The atypical adenomatous hyperplasia-adenocarcinoma sequence has been likened to the adenoma-carcinoma sequence in the large intestine. Atypical Adenomatous Hyperplasia is the earliest lesion in stepwise development of bronchioloalveolar carcinoma.By multivariate analysis, sphericity was statistically significantly associated with atypical adenomatous hyperplasia, and internal air bronchogram with bronchioloalveolar carcinoma

Read More: http://www.ajronline.org/doi/full/10.2214/AJR.07.3101

RNTCP comes out with daily regimen for drug sensitive TB

By Dr Deepu
RNTCP India has come out with a new recommendation to use daily ATT in treatment of drug sensitive tuberculosis.
The Revised National Tuberculosis Control Programme (RNTCP) was launched in India in 1997 
based on World Health Organization endorsed Directly Observed Treatment Short-Course (DOTS) 
strategy, employing the thrice weekly treatment regimen.
The Standards for TB Care in India, 2014, which were jointly laid down by Ministry of Health &  Family Welfare, Government of India and World Health Organization, in consultation with experts, based on available evidences and WHO Treatment of TB Guidelines (2010), state that ‘all patients should be given daily regimen. The initial phase should consist of two months of 
Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), and Ethambutol (E). The continuation phase should consist of three drugs, Isoniazid (H), Rifampicin (R) and Ethambutol (E) given for at least 
four months’. The National Technical Working Group (NTWG) on TB/HIV (2013) has recommended use of daily 
regimen using Fixed Dose Combination (FDC) first line TB treatment for PLHIV patients. 
Considering the above, the National Expert Committee to examine type of drug regimen for drug sensitive TB has recommended RNTCP to move towards introducing daily regimen for drug sensitive Tuberculosis in India.
The link to download the guidelines is given below. Please visit the link to download.

Download here

Classification of pneumothorax

By Dr Deepu

Cartoon showing mechanism of pneumothorax

Chest radiograph- right sided pneumothorax

chest radiograph- left sided pneumothorax

Size Classification of Pneumothorax
(A) The American College of Chest Physicians defines the size of a pneumothorax
        by the apex to cupola distance (≥3 cm large; <3 cm small).
(B) The British Thoracic Society defines the size of a pneumothorax

        by the interpleural distance measured at the hilum (≥2 cm large; <2 cm small).

Study: Acetaminophen No Better Than Placebo In Fighting Flu Symptoms

By Dr Deepu
Study: Acetaminophen No Better Than Placebo In Fighting Flu Symptoms .The New York Times (12/9, Bakalar) reports “a randomized trial has found that” acetaminophen “is no more effective than a placebo, with no discernible effect at all on reducing fever or other flu symptoms.” The study was performed by researchers at Medical Research Institute of New Zealand, and is published in Respirology.

It was a randomized, double-blind, placebo-controlled trial of adults aged 18–65 years with influenza-like illness and positive influenza rapid antigen test. Treatments were given with 1 g paracetamol four times a day, or matching placebo, for 5 days. Pernasal swabs were taken for influenza quantitative RT-PCR at Baseline and Days 1, 2 and 5. Temperature and symptom scores were recorded for 5–14 days or time of resolution respectively. The primary outcome variable was area under the curve (AUC) for quantitative PCR log10 viral load from Baseline to Day 5.

They studied  80 participants were randomized: There were 22 and 24 participants who were influenza PCR-positive in placebo and in paracetamol groups respectively. In all participants there were no differences in symptom scores, temperature, time to resolution of illness and health status, with no interaction between randomized treatment and whether influenza was detected by PCR.they therefore concluded that the regular paracetamol had no effect on viral shedding, temperature or clinical symptoms in patients with PCR-confirmed influenza. There remains an insufficient evidence base for paracetamol use in influenza infection.

Chest Challenge: chest x ray spotter

By Dr Deepu
This is a chest X ray of a 60 year old male. Presenting with history of alleged fall and right sided chest pain. His X rays are displayed here. The two X rays are 3 days apart. Observe the X rays and answer these questions.




1.What is your diagnosis?
2.The second X ray has worsened than the first one. What is the cause?
3. What can we expect in the CT thorax?

Signs in chest radiology- The hilum overlay sign

By Dr Deepu


The hilar overlay sign is another sign described by Felson.The hilum overlay sign refers to an appearance on frontal chest X ray of patients with a mass at the level of the hilum which is in fact either anterior or posterior to the hilum.




When a mass arises from the hilum, the pulmonary vessels will be in contact with the mass and hence their silhouette is obliterated. The ability to see and trace the edges of the vessels through the mass implies that the mass is not contacting the hilum, and is therefore either anterior or posterior to it. 


Most of these masses usually are found to be in the anterior mediastinum.

want to read more in chest radiology??? Have a look at the following pages

Signs in chest radiology- The silhouette Sign

By Dr Deepu
Silhouette sign/loss of silhouette sign/ loss of outline sign.
I was always confused with the silhouette sign for its hidden meaning and failure to decode it by many medical students. So, I thought it would be apt to unravel it so that it could be handy for many medical students.
One of the most useful signs in chest radiology is the silhouette sign. This sign was described by Dr. Ben Felson. The silhouette sign is in nothing but  elimination of the silhouette or loss of lung/soft tissue interface caused by a mass or fluid in the normally air filled lung. For instance, if an intrathoracic opacity is in anatomic contact with, for example, the heart border, then the opacity will obscure that border. The sign is commonly applied to the heart, aorta, chest wall, and diaphragm. The location of this abnormality can help to determine the location anatomically. 

Just go through the X Ray to know the  various structures seen in the chest x ray.

Let me explain this with this image.
What do we see???
There is plastic bottle which is surrounded by air, the margins of the shadow is very  well demarcated from the surrounding air.

First scenario: There are two bottles, made of same material, placed apart from each other. The shadows appears separate from each other. Let us consider the right bottle to be the heart and the air surrounding the bottle as lung. The left bottle as a mass, since they are far from each other, the border of both  is visible clearly.

Second scenario: Here we see the bottles are touching each other at two points and there is no gap in between and if we look at the shadow, we cannot differentiate between the two shadows, they appear like a single opacity at the upper and lower ends.


For the heart, the silhouette sign can be caused by an opacity in the RML, lingula, anterior segment of the upper lobe, lower aspect of the oblique fissure, anterior mediastinum, and anterior portion of the pleural cavity.
This contrasts with an opacity in the posterior pleural cavity, posterior mediastinum, of lower lobes which cause an overlap and not an obliteration of the heart border. Therefore both the presence and absence of this sign is useful in the localization of pathology.

want to read more in chest radiology??? Have a look at the following pages
Chest Radiology
Signs in Chest Radiology

signs in chest radiology Bulging Fissure Sign

By Dr Deepu
Bulging Fissure Sign

The bulging fissure sign, it represents expansive lobar consolidation causing fissural bulging or displacement by copious amounts of inflammatory exudate within the affected parenchyma, seen in a chest x ray. It is classically associated with right upper lobe consolidation due to Klebsiella pneumoniae , any form of pneumonia can manifest the bulging fissure sign.  The prevalence of this sign is decreasing,because of prompt administration of antibiotic therapy to patients with suspected pneumonia . The bulging fissure sign is also less commonly detected in patients with hospital-acquired Klebsiella pneumonia than in those with community-acquired Klebsiella infection .
   Other diseases that manifest a bulging fissure
 any space-occupying process in the lung, such as
pulmonary hemorrhage,
 lung abscess, and
 tumor
want to read more in chest radiology??? Have a look at the following pages

New ATS Guideline Site

By Dr Deepu

New ATS Guidelines.


The ATS has launched a one spot location for all its guidelines. Here you can find the latest ATS guidelines.Please use the guideline central to get all the guidelines.

Titles Include:

  • Severe Asthma
  • EIB
  • Pulmonary Fibrosis
  • Sleep Apnea
  • PH of Sickle Cell
  • Critical Care Series
  • and Many More

Click Here to Preview the ATS Pocket Guides

WHO Calls On India To Increase Funding To Fight TB

By Dr Deepu


Reuters (11/19, Kalra) reports that the World Health Organization said that the global fight to end a tuberculosis epidemic by 2030 hinges on India increasing funding to control the disease. Reuters notes that the country accounts for over 20 percent of global TB cases.
        Combating TB is a daunting task in India due to widespread insanitary conditions, poverty and a lack of public hospitals. Low public awareness and social stigma attached to the killer disease also hinder eradication efforts.
India also needs to upgrade laboratories to better detect the disease - the government last year tracked down 25,000 of the WHO's estimated 47,000 multi-drug resistant TB cases that, Raviglione said, was "not sufficient" but better than before.
    TB killed 1.1 million people globally last year, for the first time rivaling HIV/AIDS as a leading cause of death from infectious diseases.
"If India doesn't invest on TB, then there will be very little progress at the global level," said Raviglione.

Arsenic and permissible limits

By Dr Deepu

Arsenic is a semi-metal element in the periodic table. It is odorless and tasteless. It enters drinking water supplies from natural deposits in the earth or from agricultural and industrial practices. 
Non-cancer effects can include thickening and discoloration of the skin, stomach pain, nausea, vomiting; diarrhea; numbness in hands and feet; partial paralysis; and blindness. Arsenic has been linked to cancer of the bladder, lungs, skin, kidney, nasal passages, liver, and prostate.
EPA has set the arsenic standard for drinking water at .010 parts per million (10 parts per billion) to protect consumers served by public water systems from the effects of long-term, chronic exposure to arsenic.  Water systems must comply with this standard by January 23, 2006, providing additional protection to an estimated 13 million Americans.
EPA proposed arsenic regulations to revise the existing NPDWR on June 22, 2000 (65 FR 38888), which proposed a Maximum Contaminant Level (MCL) of 0.005 mg/L (5 μg/L). The October 2000 appropriations bill for EPA amended the SDWA, directing EPA to promulgate a final arsenic standard no later than June 22, 2001. The Final Rule, published on January 22, 2001, established the MCL at 0.01 mg/L (10 μg/L) (40 CFR 141.62(b)(16)). The Rule was to become effective on March 23, 2001, 60 days after publication. The Rule established that the 0.01 mg/L (10 μg/L) MCL becomes enforceable on January 23, 2006, and that the clarifications to compliance and new source contaminants monitoring regulations become enforceable on January 22, 2004 (40 CFR 141.6(j) & (k)).
Because of the importance of the Arsenic Rule and the national debate surrounding it related to science and costs, EPA's Administrator publicly announced on March 20, 2001, that the Agency  would take additional steps to reassess the scientific and cost issues associated with this Rule. EPA requested that the National Academy of Sciences (NAS) convene a panel of scientific experts to review the Agency's interpretation and application of arsenic research, worked with its National Drinking Water Advisory Council (NDWAC) to review the assumptions and methodologies underlying the Agency's estimate of arsenic compliance costs, and asked its Science Advisory Board (SAB) to look at the benefits associated with the Rule. On October 31, 2001, the EPA Administrator announced that the 10 ppb (0.010 mg/L) standard for arsenic would remain stating that, "the 10 ppb protects public health based on the best available science and ensures that the cost of the standard is achievable."

On January 22, 2001 EPA adopted a new standard for arsenic in drinking water at 10 parts per billion (ppb), replacing the old standard of 50 ppb.  The rule became effective on February 22, 2002.  The date by which systems must comply with the new 10 ppb standard is January 23, 2006.

Study: Arsenic Exposure In Womb Linked To Increased Respiratory Infections For Newborns

By Dr Deepu









HealthDay (11/23) reports that a new study published in the journal Environmental Health Perspectives suggests that children exposed to high levels of arsenic in the womb face an increased risk for infections and respiratory symptoms in the first year of their life. Researchers measured levels of arsenic in 412 pregnant women in New Hampshire whose homes and private wells, and they found “infants exposed to arsenic in the womb had more infections that led to a doctor visit or treatment with prescription medications.” senior author Margaret Karagas, chair of epidemiology at Dartmouth College’s School of Medicine, said in a college news release: “These results suggest that arsenic exposure may increase the risk and severity of certain types of infections.”

Read about ARSENIC and its permissible limits

FDA Approves Lung Cancer Drug

By Dr Deepu


The Wall Street Journal (11/25, B6, Steele, Subscription Publication) reports that the Food and Drug Administration announced Tuesday that it had approved Eli Lilly’s lung cancer drug, Portrazza (necitumumab). Portrazza, in combination with two forms of chemotherapy, treats patients who have advanced squamous non-small cell lung cancer and have not already received another treatment for their advanced lung cancer.
        The Indianapolis Star (11/25, Swiatek) reports that the drug “is the first biologic approved to treat patients with metastatic squamous non-small-cell lung cancer.” Although Eli Lilly did not release a price for the drug, the company “said it plans to offer a discount program to offer income-eligible patients a way to receive Portrazza for a copay of no more than $25 a dose.” 
Indicated for first-line treatment of metastatic squamous NSCLC in combination with gemcitabine and cisplatin
800 mg IV infused over 1 hr on days 1 and 8 of each 3-week cycle prior to gemcitabine and cisplatin infusion
Continue therapy until disease progression or unacceptable toxicity.
Mechanism of Action
Epidermal growth factor receptor (EGFR) inhibitor; monoclonal antibody that binds to the human EFGR and blocks interaction between EGFR and its ligands
Expression and activation of EGFR has been correlated with malignant progression, induction of angiogenesis, and inhibition of apoptosis
Pharmacokinetics
Time to steady state: ~100 days
Total systemic clearance at steady-state: 14.1 mL/hr
Vd: 7 L
Half-life: ~14 days
Adverse effects
Infusion-related reactions
  1. Grade 1: Reduce the infusion rate by 50%
  2. Grade 2: Stop the infusion until signs and symptoms have resolved to grade 0 or 1; resume infusion at 50% reduced rate for all subsequent infusions
  3. Grade 3 or 4 IRR: Permanently discontinue


Dermatologic toxicity
·         Grade 3 rash or acneiform rash: Withhold until symptoms resolve to grade ≤2, then resume infusion at reduced dose of 400 mg for at least 1 treatment cycle; if symptoms do not worsen, may increase dose to 600 mg and 800 mg in subsequent cycles
·         Permanently discontinue if
    1. Grade 3 rash or acneiform rash do not resolve to grade ≤2 within 6 wk
    2. Reactions worsen or become intolerable at a dose of 400 mg
    3. Patient experiences grade 3 skin induration/fibrosis
    4. Grade 4 dermatologic toxicity

Limitations of use: Not indicated for treatment of nonsquamous NSCLC
Hypomagnesemia (83%)
Hypocalcemia (45%)
Rash (44%)
Hypocalcemia (albumin corrected) (36%)
Hypophosphatemia (31%)
Vomiting (29%)
Hypokalemia (28%)
Hypomagnesemia, grade 3-4 (20%)
Diarrhea (16%)
Dermatitis acneiform (15%)
Weight decreased (13%)
Stomatitis (11%)
Headache (11%)
1-10%
Hemoptysis (10%)
Venous thromboembolic events (9%)
Acne (9%)
Hypophosphatemia, grade 3-4 (8%)
Paronychia (7%)
Conjunctivitis (7%)
Pruritus (7%)
Dry skin (7%)
Hypocalcemia, grade 3-4 (6%)
Hypokalemia, grade 3-4 (5%)
Skin fissures (5%)
Pulmonary embolism (5%)
Venous thromboembolic events, grade 3-4 (5%)
Hypocalcemia (albumin corrected), grade 3-4 (4%)
Vomiting, grade 3-4 (3%)
Diarrhea, grade 3-4 (2%)

Global Plan to End TB to Save Over 10 Million Lives

By Dr Deepu

The world is losing its battle with tuberculosis, which is now the biggest infectious killer globally, causing 1.5 million deaths every year, according to the new GlobalPlan to End TB 2016-2020, which was released Nov. 20 by the Stop TB Partnership. The plan’s targets, called 90-(90)-90, are aiming for 90 percent rates in the three areas of: TB diagnosis, care for vulnerable populations, and treatment. New tools are needed for successful implementation, and the Global Plan calls for an additional $9 billion to create a vaccine, rapid diagnostic tests, and drug regimens (including for drug-resistant TB). The plan will be shared with high-level politicians from around the world at the 46th Union World Conference on Lung Health in Cape Town, South Africa, in December.

Top FDA Official Says Regulators Should Consider Potential Benefits Of E-Cigarettes

By Dr Deepu


The Congressional Quarterly (10/22, Siddons, Subscription Publication) reports that Mitch Zeller, head of the Food and Drug Administration’s Center for Tobacco Products, said Wednesday that regulators have to consider the possible health benefits for smokers who transition to e-cigarettes. “If there is an opportunity to shift those unable or unwilling to quit from the most harmful form of nicotine delivery, to the least harmful form,” Zeller said, “then I think that we as regulators have an opportunity to explore what those options are. “

Fauci Optimistic About The Development Of A Universal Flu Vaccine Within Next 5 To 10 Years

By Dr Deepu


In a 1,500-word article, NBC News (10/20) reports on its website on this year’s flu vaccine, the market environment, and the push for vaccination. The piece also reports on the “holy grail for flu: A universal vaccine,” which is currently being pursued at the National Institutes of Health. National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci “said he’s optimistic a universal vaccine is five to 10 years away.” In an interview, Fauci said, “I think that we are making extraordinary progress and we can sort of see that light at the end of the tunnel.” He added, “If we can successfully induce a response against that stem part of that protein, we’re going to be very close to developing a universal flu vaccine.” In the meantime, public health researchers “emphasized the best thing the public can do to avoid spread of the flu is to wash hands, cover coughs and sneezes…and get vaccinated.”

Sleep Apnea May Be More Dangerous For Women Than For Men

By Dr Deepu


The New York Times (10/20, D6, Bakalar) “Well” blog reports that research published in Circulation suggests that “sleep apnea may be even more dangerous for women than for men.” Investigators found that “obstructive sleep apnea was independently associated with increased troponin T, heart failure and death in women, but not in men.” The researchers also found that “in women, but not men, sleep apnea was associated with an enlarged heart, another risk factor for cardiovascular disease.”

Normal Vocal Cords

By Dr Deepu


CDC: Teen Smoking Rates Declining, Marijuana Use On The Rise

By Dr Deepu


HealthDay (10/16, Reinberg) reports that according to today’s MMWR, the CDC says that smoking among teenagers has dropped 64 percent in recent years, but marijuana use has more than doubled. Investigators “tracked teen smoking rates from 1997 to 2013.” The researchers found that “overall, the number of teens who smoked cigarettes or cigars dropped from 20.5 percent to slightly more than 7 percent, while marijuana use went from 4 percent to 10 percent.”

EV-D68 No More Deadly Than Common Cold Germs, Study Finds

By Dr Deepu


HealthDay (10/16, Thompson) reports that a new study conducted at McMaster University in Ontario, Canada suggests that enterovirus D68, which made headlines in 2014 after sickening children across North America, is “no more deadly than other common cold germs.” For the study, the researchers compared “87 kids treated for EV-D68 at McMaster Children’s Hospital with 87 kids who caught a rhinovirus or some other enterovirus at the same time.” The findings were published in the Canadian Medical Association Journal. Medscape (10/16) also covers the story.

Sleep Apnea May Increase A Woman’s Risk For Heart Problems

By Dr Deepu


HealthDay (10/15, Preidt) reports that research indicated that “sleep apnea can boost a woman’s risk for heart problems and even death, but there was no such effect for men.” The study also indicated that, “compared to women without sleep apnea, women with the disorder had higher blood levels of troponin, a chemical signal of early heart damage.” The study was published in Circulation.

Kartageners Syndrome

By Dr Deepu
See the question
The answer is b."Kartagener syndrome"

Kartagener syndrome is the inheritable disorder of dextrocardia, chronic sinusitis (with the formation of nasal polyps), and bronchiectasis. Patients may also present with situs inversus.The disorder is due to a defect that causes the cilia within the respiratory tract epithelium to become immotile. Cilia of the sperm are also affected

Chest Challenge MCQ - Give your diagnosis

By Dr Deepu
A teenage boy presents with a history of chronic sinusitis and frequent pneumonias. On physical examination, the patient has normal vital signs and is afebrile. He has mild frontal and maxillary sinus tenderness with palpation. Transillumination of the sinuses is normal. Heart sounds are best heard on the right side of the chest. The boy is coughing copious amounts of yellowish sputum. The chest X ray is shown.
Which of the following is the most likely diagnosis?
a.Cystic fibrosis
b.Kartagener syndrome
c.Pulmonary dysplasia
d.Tuberculosis

e.Pulmonary hypertension


Experts question the evidence underpinning e-cigarette recommendations

By Dr Deepu
Concern over Public Health England's recent support for e-cigarettes
Public Health England (PHE) recently endorsed the use of electronic cigarettes as an aid to quitting smoking. But in The BMJ this week, experts question the evidence on safety and effectiveness underpinning the recommendations.
Professor Martin McKee at the London School of Hygiene The BMJ Tropical Medicine and Professor Simon Capewell at the University of Liverpool, argue that the available evidence about e-cigarettes "suggests that the debate is far from over and questions remain about their benefits and harms."
The PHE report concludes that e-cigarettes are much safer than conventional cigarettes. It also says there is no evidence that e-cigarettes give children a "gateway" into smoking.
Some of the findings have been welcomed by Action on Smoking and Health (ASH) and the Royal College of Physicians of London. But other leading health bodies - including the British Medical Association, the US Centers for Disease Control and Prevention, and the World Health Organization - have expressed caution.
So does the available evidence show clearly that e-cigarettes are as effective as established quitting aids, ask McKee and Capewell.
Unfortunately not. For example, a recent Cochrane review, widely cited in the PHE report, concluded the available evidence was of "low or very low quality" by recognised standards.
And a recent systematic review, which the PHE report surprisingly fails to cite, also found serious methodological problems in many of the studies it reviewed, and noted that one third of the studies (34%) it reviewed were published by authors with conflicts of interest.
The headline message from the PHE report is that "best estimates show e-cigarettes are 95% less harmful to your health than normal cigarettes." Yet McKee and Capewell point out that this figure comes from a single meeting of 12 people, involving several known e-cigarette champions and sponsored by companies with links to the tobacco industry.
The PHE report also asserts that the available evidence suggests that e-cigarettes are not currently re-normalising smoking among children and young people in the UK. But McKee and Capewell point out that experimentation with e-cigarettes among young people in England is "worryingly high" and "this remains a major concern for health professionals and parents."
They describe the report's dismissal of the possibility that e-cigarettes may be a gateway to smoking as "premature." And they argue that the report has many other omissions, such as concerns about product safety, and the lack of evidence of risks from long term dual use with conventional cigarettes.
Finally, the PHE summary states, "The accuracy of nicotine content labelling currently raises no major concerns." Surely, England's leading public health agency cannot be indifferent to a situation in which consumer product information is known to be wildly inaccurate, they ask.
In 2017, the European Union Tobacco Products Directive will come into force, with substantial restrictions on e-cigarettes. "These restrictions will hopefully limit the negative effect of this flawed PHE report," say TheBMJ article's authors.
"Meanwhile, directors of public health and the wider community desperately need advice on e-cigarettes that is evidence based and free from any suspicion of influence by vested interests," they conclude.
Link to full article

Banning trans fats in England could prevent 7,000 heart deaths over next five years

By Dr Deepu
A total ban is technically feasible and decisive action is now needed, say experts
A total ban on trans fatty acids (trans fats) in processed foods in England could potentially prevent or postpone about 7,200 deaths from coronary heart disease over the next five years, suggest experts in TheBMJ this week.
They say a total ban in England is "technically feasible" and they call for "decisive action" to prioritise the most effective and cost effective policy options.
Industrial trans fatty acids are produced from plant oils (a process known as hydrogenation) and are commonly added to processed foods to cheaply improve shelf life and palatability.
Higher intake of these fats is associated with increased risk of coronary heart disease and death, and consumption is generally higher in lower socioeconomic groups. Their elimination from the UK diet is part of the Department of Health's responsibility deal.
So a team of researchers decided to evaluate three policy options to reduce consumption of trans fats in England: a total ban on trans fatty acids in processed foods; improved food labelling; and bans on trans fatty acids in restaurants and takeaway outlets.
They calculated health and equity benefits and cost effectiveness of each policy compared with consumption remaining at most recent levels. Influential factors such as age, sex, and socioeconomic status were taken into account.
Guidelines currently recommend that trans fats are limited to less than 1% of energy intake. The researchers calculated that average consumption of trans fatty acids among UK adults in 2001-09 to 2011-12 was around 0.7% of energy intake. For the most disadvantaged groups, consumption was higher, around 1.3%.
The researchers found that a total ban on industrial trans fatty acids in processed foods in England might potentially prevent or postpone about 7,200 deaths (2.6%) from coronary heart disease from 2015-20 and reduce inequality in mortality from coronary heart disease by about 3,000 deaths (15%).
This inequality stems from the fact that early death from coronary heart disease is substantially higher among the most disadvantaged socioeconomic groups compared with the most affluent.
Policies to improve labelling or simply remove trans fatty acids from restaurants and takeaways could save between 1,800 (0.7%) and 3,500 (1.3%) deaths from coronary heart disease and reduce inequalities by 600 (3%) to 1,500 (7%) deaths, thus making them at best half as effective.
A total ban would also have the greatest net cost savings of The BMJ264m excluding product reformulation costs, or The BMJ64m if substantial reformulation costs are incurred.
"Elimination of trans fatty acids from processed foods is an achievable target for public health policy," say the authors. Such a ban "would lead to health benefits at least twice as large as other policy options, both in terms of total population benefit and reduction in inequality."
They suggest that continuing to rely on industry cooperation via the responsibility deal "might be insufficient" and call for "decisive action" to prioritise the most effective and cost effective policy options.
There's nothing good about industrial trans fats and a total ban would be best for public health, argues Lennert Veerman from the University of Queensland's School of Public Health, in an accompanying editorial.
"Given the clear evidence on the health impact of trans fats and what we know about consumption patterns, rates of heart disease, and related economic costs in England, we can safely conclude that these actions to accelerate the removal of industrial trans fat from the food supply are good for health, cost saving, and equitable," he writes.
Link to full study
Link to editorial

Increasing calcium intake unlikely to boost bone health or prevent fractures, say experts

By Dr Deepu
Increasing intake through diet or supplements should not be recommended for fracture prevention
Increasing calcium intake through dietary sources or supplements is unlikely to improve bone health or prevent fractures in older people, conclude two studies published in The BMJ this week. Collectively, these results suggest that increasing calcium intake, through supplements or dietary sources, should not be recommended for fracture prevention.
Guidelines advise older men and women to take at least 1000-1200 mg/day of calcium to improve bone density and prevent fractures, and many people take calcium supplements to meet these recommendations. Recent concerns about the safety of calcium supplements have led experts to recommend increasing calcium intake through food rather than by taking supplements, but the effect on bone health is unknown.
So a team of researchers in New Zealand set out to examine the evidence underpinning recommendations to increase calcium intake from dietary sources or supplements to improve bone health and prevent fractures.
They analysed the available evidence from randomised controlled trials and observational studies of extra dietary or supplemental calcium in women and men aged over 50. Study design and quality were taken into account to minimise bias.
In the first study, they found that increasing calcium intake from dietary sources or by taking supplements produces small 1-2% increases in bone mineral density, which "are unlikely to lead to a clinically meaningful reduction in risk of fracture."
In the second study, they found that dietary calcium intake is not associated with risk of fracture, and there is no clinical trial evidence that increasing calcium intake from dietary sources prevents fractures.
It is time to revisit recommendations to increase calcium intake beyond a normal balanced diet, argues Professor Karl Michaƃ«lsson from Uppsala University in Sweden, in an accompanying editorial.
He points out that ever increasing intakes of calcium and vitamin D recommended by some guidelines defines virtually the whole population aged over 50 at risk. Yet most will not benefit from increasing their intakes, he warns, and will be exposed instead to a higher risk of adverse events.
"The weight of evidence against such mass medication of older people is now compelling, and it is surely time to reconsider these controversial recommendations," he concludes.